LY333531 for diabetic retinopathy - horizon scanning review

Record ID 32002000540
Authors' objectives:

To summarise the current research evidence on LY333531 (protein kinase C inhibitor) for diabetic retinopathy.

Authors' recommendations: - Clinical impact: There are no published efficacy trials so no assessment of clinical impact can be made. However LY333531 is a new class of drug for diabetic eye disease and would directly compete with laser photocoagulation with its attendant sequelae. - Service impact: Local screening programmes for diabetic retinopathy and maculopathy are already in place and a national screening programme is under discussion. If an oral therapy could achieve the same results as photocoagulation then a positive impact on demand for the treatment of retinopathy could be anticipated. - Additional factors: There is likely to be significant professional and patient interest in the continuing development and eventual access to LY333531. - Financial and overall NHS impact: Although it is difficult to determine the likely financial impact of the introduction of LY333531, it may be significant due to its novelty, the size of the potential patient group and the continuing introduction of retinal screening programmes.
Authors' methods: Overview
Project Status: Completed
Year Published: 2002
URL for published report:
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Diabetic Retinopathy
  • Protein Kinase C
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
Contact Email:
Copyright: National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.